Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib combined with cranial radiotherapy for ALK-positive non-small cell lung cancer with brain metastases
ChiCTR2400093994Phase 2Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ensartinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: Progression-free survival and Intracranial progression-free survival. Started Dec 2024; status: recruiting.
02
Drugs
ensartinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400093994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093994.